Melbourne, Australia, 22 June 2016: Neuren Pharmaceuticals (ASX: NEU) today announced that IP Australia has issued a Notice of Grant for a new patent that covers the use of trofinetide for the treatment of Autism Spectrum Disorders, including Rett syndrome, Fragile X syndrome, Asperger syndrome and autism. Patent number AU2012209466 expires in January 2032.
Ann: Grant of new patent for Autism Spectrum Disorders-NEU.AX, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.84 |
Change
-0.260(1.98%) |
Mkt cap ! $1.597B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $2.860M | 218.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 177 | $12.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 161 | 5 |
View Market Depth
| Last trade - 13.45pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |